Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/07/2020 08/10/2020 08/11/2020 08/12/2020 08/13/2020 Date
8470(c) 8380(c) 8450(c) 8699(c) 8542(c) Last
991 924 983 530 1 190 457 1 587 030 1 022 735 Volume
+0.61% -1.06% +0.84% +2.95% -1.80% Change
More quotes
Financials (USD)
Sales 2020 26 712 M - -
Net income 2020 3 067 M - -
Net Debt 2020 13 578 M - -
P/E ratio 2020 52,1x
Yield 2020 2,48%
Sales 2021 30 059 M - -
Net income 2021 4 325 M - -
Net Debt 2021 11 695 M - -
P/E ratio 2021 37,4x
Yield 2021 2,51%
Capitalization 146 B 147 B -
EV / Sales 2020 5,98x
EV / Sales 2021 5,25x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
More about the company
Surperformance© ratings of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
02:04pEU to enter contract talks with J&J over 200 million doses of potential COVID..
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
12:17pASTRAZENECA : Mexico, Argentina to Produce Potential AstraZeneca Coronavirus Vac..
DJ
12:14pU.S. recruits scientists abroad for COVID-19 vaccine trials, pledges access t..
RE
10:11aEUROPE : European stocks end four-day winning run as UK's FTSE drags
RE
08:19aVaccine ETA? Depends who you ask
RE
08:03aIndian drugmaker Biological E. to make substance used in J&J's potential COVI..
RE
07:31aASTRAZENECA : Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Se..
BU
08/13ASTRAZENECA PLC : Ex-dividend day for interim dividend
FA
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
RE
08/11J&J eyes 1 billion doses of potential COVID-19 shot in 2021, weighs challenge..
RE
08/11ASTRAZENECA : Partners with Actor and Author Tony Hale to Build Awareness of Eos..
BU
08/11Sinovac launches Phase 3 trial for COVID-19 vaccine in Indonesia, reports Pha..
RE
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
More news
News in other languages on ASTRAZENECA PLC
02:04pEU to enter contract talks with J&J over 200 million doses of potential COVID..
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
12:17pASTRAZENECA : Mexico, Argentina to Produce Potential AstraZeneca Coronavirus Vac..
12:14pU.S. recruits scientists abroad for COVID-19 vaccine trials, pledges access t..
10:11aEUROPE : European stocks end four-day winning run as UK's FTSE drags
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 113,90 $
Last Close Price 113,49 $
Spread / Highest target 28,3%
Spread / Average Target 0,36%
Spread / Lowest Target -47,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.36%148 927
JOHNSON & JOHNSON0.75%394 028
ROCHE HOLDING AG1.08%297 694
PFIZER, INC.-2.17%212 995
MERCK & CO., INC.-9.09%209 118
NOVARTIS AG-15.76%187 147